full year

Showing 2 posts of 2 posts found.

valeant_logo

Valeant cuts 2016 sales, earnings outlook; shares plunge over 47%

March 15, 2016
Business Services, Manufacturing and Production, Sales and Marketing Valeant Pharma, fourth quarter, full year, results

Valeant Pharmaceuticals Inc (NYSE: VRX) cut its outlook for the first-quarter of 2016 and posted a loss for the final …

Boehringer assures future growth following sales drop

April 23, 2015
Sales and Marketing Boehringer, COPD, Glyxambi, Striverdi Respimat, empagliflozin, empagliflozin/linagliptin, financials, full year, jardiance, nintedanib, ofev, olodaterol, results

Boehringer says it is positioned for future growth in the wake of filing a decline in profit for 2014 and …

The Gateway to Local Adoption Series

Latest content